Encouraging results were also observed in TP53-mutated patients receiving combined treatment comprising magrolimab and azacitidine, and the CR and marrow complete remission (mCR) rates of TP53-mutated MDS patients were 38% and 13%, respectively. Here, TP53 is linked to myelodysplastic syndrome.